6-K
Afya Ltd (AFYA)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORTOF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October, 2021
CommissionFile Number: 001-38992
Afya Limited
(Exact name of registrant as specifiedin its charter)
Alameda Oscar Niemeyer, No. 119,Salas 502, 504, 1,501 and 1,503
Vila da Serra, Nova Lima, Minas Gerais
Brazil
+55 (31) 3515 7550
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
| Form 20-F | X | Form 40-F |
|---|
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
| Yes | No | X |
|---|
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
| Yes | No | X |
|---|
TABLE OF CONTENTS
| EXHIBIT | |
|---|---|
| 99.1 | Afya Limited Announces the Acquisition of RX PRO |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Afya Limited | ||
|---|---|---|
| By: | /s/ Virgilio Deloy Capobianco Gibbon | |
| Name: | Virgilio Deloy Capobianco Gibbon | |
| Title: | Chief Executive Officer |
Date: October 1, 2021
FOR IMMEDIATE RELEASE:
Afya Limited Announces the Acquisition of RX PRO
October 01, 2021 – Afya Limited, or Afya (Nasdaq: AFYA) today announced the acquisition of 100% of the total share capital of RX PRO, a solution that connects physicians with the pharmaceutical industry, providing specialized and personalized marketing for those companies, in a more convenient way for physicians. RX PRO does this by delivering free samples to a community of pre-selected physicians and offering medical updates regarding pharmaceutical products and treatments in a fast and efficient way for doctors.
RX PRO has already delivered free samples to more than 45,000 physicians with an innovative digital experience, with an NPS of 83 and as of today has more than 12 pharmaceutical companies using its platform. The Company has an expected gross revenue for 2021 of R$8.9 million.
RX PRO incorporates the digital prescription pillar and further strengthens Afya's digital ecosystem thesis.
The aggregate purchase price (enterprise value) paid to sellers was R$35.4 million, of which 85% was paid in cash and 15% is paid in Afya Stocks. An earn-out of up to R$21 million can be paid related to gross revenue achievements for 2022, 2023 and 2024.
About Afya
Afya is a leading medical education group in Brazil based on number of medical school seats, delivering an end-to-end physician-centric ecosystem that serves and empowers students and physicians to transform their ambitions into rewarding lifelong experiences from the moment they join us as medical students through their medical residency preparation, graduation program, continuing medical education activities and offering digital products to help doctors enhance their healthcare services through their whole career.
Contact: Investor Relations: [email protected]